Top Page
Philogen SpA
(Stuttgart:PHIL)
Philogen SpA (PHIL) vs. iShares MSCI Italy ETF (EWI)
Philogen SpA Business Overview & Revenue Model
Philogen SpA Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 74.00M | 23.13M | 23.71M | 2.50M | 4.78M | Gross Profit |
| 54.42M | 5.67M | 10.53M | -8.14M | -5.05M | EBIT |
| 37.73M | -8.84M | 240.00K | -16.77M | -12.13M | EBITDA |
| 44.75M | -2.05M | -1.19M | -12.98M | -10.53M | Net Income Common Stockholders |
| 45.29M | -6.16M | -5.38M | -15.72M | -13.29M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 113.73M | 75.34M | 86.20M | 101.68M | 61.94M | Total Assets |
| 168.45M | 119.27M | 125.83M | 132.75M | 85.47M | Total Debt |
| 11.51M | 14.91M | 11.89M | 11.84M | 11.98M | Net Debt |
| -19.07M | -720.00K | -12.54M | 2.96M | 23.00K | Total Liabilities |
| 29.80M | 28.68M | 27.91M | 27.67M | 29.80M | Stockholders Equity |
| 138.66M | 90.59M | 97.92M | 105.09M | 55.67M |
| Cash Flow | Free Cash Flow | |||
| 38.67M | -10.69M | -9.15M | -25.85M | -16.81M | Operating Cash Flow |
| 40.84M | -4.82M | -4.94M | -19.03M | -13.16M | Investing Cash Flow |
| -22.28M | 159.00K | 24.20M | -47.77M | 17.77M | Financing Cash Flow |
| -3.78M | -4.17M | -3.78M | 63.05M | 3.79M |
Philogen SpA Technical Analysis
Philogen SpA Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | €657.96M | 24.20 | 39.51% | ― | 219.91% | ― | |
54 Neutral | $5.38B | 3.40 | -45.06% | 3.28% | 16.75% | -0.02% | |
| €1.67B | 7.84 | 30.06% | 11.78% | ― | ― | ||
| €5.20B | 28.25 | 11.27% | 1.26% | ― | ― | ||
| €41.61B | 16.38 | 4.83% | 7.31% | ― | ― | ||
| €1.79B | 43.28 | 14.13% | 0.25% | ― | ― | ||
| €16.69B | 23.80 | 15.32% | 1.37% | ― | ― |
Philogen SpA Corporate Events
Philogen’s subsidiary, Philochem AG, has licensed the worldwide rights to OncoACP3, a new therapeutic and diagnostic agent for prostate cancer, to RayzeBio, a Bristol-Myers Squibb subsidiary, in a deal worth up to $1.35 billion plus royalties. This agreement marks a significant milestone, enhancing RayzeBio’s position in the radiopharmaceutical sector and promising a groundbreaking treatment option for prostate cancer, with Philochem receiving an initial payment and potential milestone payments, subject to regulatory approvals expected by the third quarter of 2025.
The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.
Philogen S.p.A. has announced an update on its share buyback program, revealing the purchase of 790 shares at an average price of Euro 22.50 per share, totaling Euro 17,775.00. Since the program’s inception, the company has acquired 14,742 shares, representing 0.0363% of its share capital, which may impact its market positioning and shareholder value.
The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.
Philogen S.p.A. has made available the minutes of its Shareholders’ Meeting held on April 29, 2025. This announcement underscores the company’s commitment to transparency and governance, potentially reinforcing stakeholder confidence and supporting its strategic objectives in the biotechnology sector.
The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.
Philogen S.p.A. announced an update on its share buyback program, revealing the purchase of 1,800 shares between May 19 and May 23, 2025, at an average price of Euro 22.30 per share, totaling Euro 40,140.00. Since the program’s inception, the company has acquired 13,952 shares, representing 0.0344% of its share capital, with a total value of Euro 309,433.85. This move is part of Philogen’s strategy to manage its capital structure and potentially increase shareholder value, reflecting confidence in its ongoing operations and future prospects.
The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.
Philogen S.p.A. announced an update on its share buyback program, revealing the purchase of 7,628 shares between May 12 and May 16, 2025, at an average price of Euro 22.3742 per share, totaling Euro 170,670.65. This move is part of a broader strategy to enhance shareholder value and demonstrates the company’s commitment to its investors. The buyback program, since its inception, has seen the acquisition of 12,152 shares, representing 0.0299% of the share capital, indicating Philogen’s proactive approach in managing its equity and reinforcing its market position.
The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.
Philogen S.p.A. has announced an update on its share buyback program, revealing the purchase of 4,524 shares from May 7 to May 9, 2025, representing 0.0111% of its share capital at an average price of Euro 21.80 per share. This move is part of a broader strategy approved by the Board of Directors and Shareholders’ Meeting, reflecting the company’s commitment to enhancing shareholder value. As of May 9, 2025, Philogen holds a total of 336,674 ordinary shares, equating to 0.8290% of its share capital, indicating a strategic approach to managing its equity and potentially impacting its market positioning.
The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.
Philogen S.p.A. reported a positive net financial position of €93.574 million for the first quarter of 2025, despite a decrease from the previous quarter. The company is progressing with its main trials, Nidlegy™ and Fibromun, and has initiated a share buyback program. The Board of Directors has also reconstituted key committees and noted significant advancements in their industrial programs. These developments reflect Philogen’s strategic focus on expanding its clinical pipeline and maintaining financial stability, which could enhance its position in the biopharmaceutical industry.
Philogen S.p.A.’s Shareholders’ Meeting approved the 2024 financial statements, allocating a net profit of over 45 million euros to reserves. The meeting also appointed a new Board of Directors, with Dr. Duccio Neri as Chairman, and approved amendments to incentive plans for employees and directors, including a stock grant plan and a shareholding plan.
Philogen S.p.A. announced the purchase of 6,120 of its own shares as part of its ongoing share buyback program, approved by the Board of Directors in December 2024. This transaction, conducted on the Euronext Milan market, represents 0.0151% of the company’s share capital. Since the start of the buyback program, Philogen has acquired a total of 55,776 shares, equivalent to 0.1373% of its share capital, reflecting a strategic move to consolidate its market position and potentially enhance shareholder value.
Philogen S.p.A. has announced the total amount of voting rights ahead of its upcoming Shareholders’ Meeting. The company disclosed that its share capital consists of 40,611,111 shares, translating to 63,347,611 voting rights. This announcement underscores Philogen’s commitment to transparency and provides stakeholders with crucial information about its governance structure, potentially impacting investor confidence and market perception.
Philogen S.p.A. has announced the submission of a list of candidates for the appointment of its Board of Directors, which will be decided at the upcoming shareholders’ meeting. The list, presented by major shareholder Nerbio S.r.l., includes ten candidates, with Dr. Duccio Neri proposed as Chairman. This move is part of the company’s adherence to regulatory and statutory provisions, ensuring compliance with governance codes, and aims to solidify its leadership structure.
Philogen S.p.A. announced an update on its share buyback program, revealing the purchase of 8,199 shares, representing 0.0202% of its share capital, for a total of Euro 162,240.01 between March 31 and April 4, 2025. This move is part of a broader strategy to manage its capital structure, with the company having acquired a total of 49,656 shares since the program’s inception. The buyback program reflects Philogen’s commitment to enhancing shareholder value and optimizing its financial resources.
Philogen S.p.A. announced an update on its share buyback program, revealing the purchase of 6,473 shares between March 24 and March 28, 2025, at an average price of Euro 19.4810 per share, totaling Euro 126,100.61. This move is part of a broader strategy to manage capital structure, with the company having acquired a total of 41,457 shares since the program’s inception. The buyback program reflects Philogen’s confidence in its market positioning and aims to enhance shareholder value.
Philogen S.p.A. has released documentation related to its upcoming shareholders’ meeting on April 29, 2025. The documents include explanatory reports on various agenda items such as financial statements, remuneration policy, incentive plans, and proposals for share capital increase. These documents are available on the company’s website and through authorized storage mechanisms. The announcement highlights Philogen’s ongoing efforts to engage with shareholders and manage its financial and strategic planning, potentially impacting its market position and stakeholder interests.
Philogen S.p.A. reported a significant financial turnaround in 2024, achieving record profits with revenues tripling from the previous year. The company is advancing its product pipeline with key developments including the ongoing evaluation of Nidlegy™ for melanoma by EMA, promising results in radiopharmaceuticals, and a new collaboration with Sun Pharma for Fibromun. These advancements underscore Philogen’s strengthened position in the biotechnology sector and its commitment to innovative cancer treatments.
Philogen S.p.A. has announced a meeting for its shareholders to discuss and resolve various financial and governance matters. The agenda includes approval of financial statements, remuneration policies, and the appointment of a new Board of Directors. Additionally, the meeting will address amendments to incentive plans and authorize the purchase and disposal of own shares, reflecting the company’s strategic focus on enhancing shareholder value and aligning management incentives.
Philogen S.p.A. has announced an update on its share buyback program, revealing the purchase of 1,887 shares between March 10 and March 14, 2025, at an average price of Euro 18.6538 per share, totaling Euro 35,199.73. This move is part of a broader strategy, with the company having acquired 34,984 shares since the program’s inception, reflecting its commitment to enhancing shareholder value and potentially signaling confidence in its market position.